MedPath

Tagged News

FDA Clears First AI-Powered Wristband for Essential Tremor Treatment

AI
  • The FDA has granted 510(k) clearance for the Felix NeuroAI Wristband, the first AI-driven wearable device approved for treating tremor-related functional limitations in adults with essential tremor.
  • The noninvasive device connects to a cloud-based AI platform to deliver personalized, adaptive stimulation throughout the day, offering an alternative to surgery and medications for the approximately 7 million Americans affected by essential tremor.
  • Clinical trial data from the TRANQUIL study demonstrated significant tremor reduction and improved daily function with no serious device-related side effects, with the device expected to be available by prescription in select U.S. regions in 2025.

Philips Receives FDA Clearance for AI-Powered MRI Software That Accelerates Scans by 3x

AI
  • Philips has received FDA 510(k) clearance for SmartSpeed Precise, an AI-powered MRI reconstruction tool that can scan up to three times faster while producing images up to 80% sharper than earlier methods.
  • The software integrates Philips' Compressed SENSE acceleration engine with dual AI models for denoising and image sharpening, offering a single-click workflow to address staff shortages and patient backlogs.
  • Clinical testing at University Hospital Bonn demonstrated breast MRI acquisition times reduced by up to 50% with improved image quality compared to previous protocols.
  • The technology is now available for all Philips 1.5-tesla and 3-tesla MRI systems, including existing installed base systems as an upgrade option.

Argon AI Secures $5.5M to Transform Pharmaceutical Data Management with AI-Native Workspace

AI
  • Argon AI raised $5.5 million in seed funding led by Crosslink Capital and Wireframe Ventures to develop an AI-native workspace specifically designed for life sciences companies.
  • The platform addresses critical inefficiencies in pharmaceutical data management, where internal data doubles every two years and teams process tens of thousands of documents annually in unwieldy formats.
  • Argon's AI-enabled workspace integrates internal company data with proprietary clinical and commercial databases, automating tasks like market research, competitive tracking, and clinical trial benchmarking.
  • The company is already working with two top-15 global pharmaceutical companies and deployed at premier consulting firms, with potential to save millions in misdirected R&D spending.

Quiver Bioscience Secures $2.15M NIH Grant to Develop AI-Powered CNS Drug Safety Platform

AI
  • Quiver Bioscience received a $2.15 million Phase II SBIR grant from the National Institute of Neurological Disease and Stroke to develop an integrated platform for predicting safety of CNS-targeted antisense oligonucleotide therapeutics.
  • The three-year "Safe-OPTION" project will combine machine learning-based in silico ASO design tools with all-optical electrophysiology platform-based in vitro neuronal functional assays to better predict ASO CNS toxicity.
  • The enhanced platform aims to accelerate ASO drug development by rapidly identifying lead molecules with better probability of clinical success while reducing costs and time associated with preclinical animal studies.
  • Quiver's drug discovery platform combines disease-relevant human neuronal models, all-optical electrophysiology-based functional readouts, and AI/ML-enabled analytics to provide insights into neurological disorders.

Rush University Medical Center Launches First-Ever Apple Vision Pro Colonoscopy Study with AI Integration

AI
  • Rush University Medical Center will begin the world's first clinical study in July 2025 integrating Apple Vision Pro with Medtronic's GI Genius AI module for real-time colonoscopy guidance.
  • The innovative system allows physicians to view AI-generated polyp detection insights directly in their field of vision without looking away from the procedure screen.
  • The study results will support Cosmo Pharmaceuticals' planned FDA submission for what could become the first FDA-cleared medical software application on Apple Vision Pro.
  • The GI Genius AI module has already demonstrated the ability to increase adenoma detection rates by up to 14.4% in colorectal cancer screening procedures.

Senzime Secures Major U.S. Hospital Contract and New Patent for TetraGraph Neuromuscular Monitoring System

AI
  • Senzime has secured a contract with one of the largest U.S. university hospital systems to supply 63 TetraGraph monitors for deployment in Texas, targeting standardized neuromuscular monitoring for over 27,000 patients annually.
  • The company received a new U.S. patent protecting key algorithms in the TetraGraph system that enhance electromyography-based signal quality by filtering out operating room noise.
  • The TetraGraph system is currently used in over 4,000 operating rooms worldwide and aligns with recent U.S. and European guidelines recommending quantitative neuromuscular monitoring for all patients receiving neuromuscular blocking agents.
  • Senzime's patent portfolio has grown to 107 issued patents, reinforcing the company's competitive position in personalized anesthesia solutions and perioperative patient safety.

Imagene AI Secures $23M Series B Led by Larry Ellison to Advance Multi-Modal Foundation Models for Precision Medicine

AIPrecision Medicine
  • Imagene AI completed a $23 million Series B funding round led by Oracle Chairman Larry Ellison, bringing total funding to $45 million for developing multi-modal foundation models in precision medicine.
  • The company's platform integrates histopathology, molecular profiles, and clinical data through proprietary foundation models to enable real-time analysis and personalized treatment decisions.
  • Imagene AI has developed a digital pathology foundation model trained on over 1.5 million biopsy images and launched the OI Suite platform for biomarker discovery and patient identification.
  • The company is expanding strategic collaborations, including a partnership with Tempus to deliver predictive assays for treatment guidance in clinical settings.

Healx Partners with SCI Ventures in $2M AI-Driven Initiative to Develop Spinal Cord Injury Treatments

AIDrug DiscoveryRare Disease
  • Healx has partnered with SCI Ventures in a $2 million collaboration to apply AI-powered drug discovery to spinal cord injury, which affects over 20 million people globally with limited treatment options.
  • The partnership combines Healx's machine learning expertise with SCI Ventures' neuroregeneration domain knowledge and unique dataset access to target chronic spinal cord injury treatments.
  • The collaboration aims to dramatically shorten the path from discovery to clinical application by prioritizing AI-driven target discovery and drug repurposing strategies.
  • Success in spinal cord injury could open doors to AI-powered therapies for other neurological conditions including traumatic brain injury, stroke, ALS, multiple sclerosis, Parkinson's, and Alzheimer's disease.

DRC Medicine Announces $422 Million SPAC Merger to Advance Therapeutic Mask Technology and Parkinson's Drug Pipeline

AI
  • DRC Medicine, a Japanese biotechnology company, announced a business combination agreement with Ribbon Acquisition Corp that values the combined company at approximately $422.15 million and will provide $50.42 million in cash proceeds.
  • The company is developing the world's first therapeutic masks for seasonal allergic rhinitis using proprietary Hydro Silver Titanium® technology and advancing a pipeline of AI-powered diagnostic kits for infectious diseases.
  • DRC Medicine is in final negotiations to acquire an innovative ATP-enhancing drug for Parkinson's disease that is currently in clinical trials, expanding its therapeutic portfolio.
  • Current DRC Medicine shareholders will retain 100% of their equity and own approximately 82.91% of the combined company, which is expected to be listed on NASDAQ Global Market.

Tempus AI Raises $650 Million Through Convertible Notes to Advance AI-Driven Precision Medicine Platform

AIPrecision Medicine
  • Tempus AI successfully priced a $650 million convertible senior notes offering, increasing from the initially announced $400 million, to fund its AI-enabled precision medicine platform development.
  • The company plans to use approximately $274.7 million of proceeds to repay existing debt and $36.2 million for capped call transactions, with remaining funds allocated to general corporate purposes including potential acquisitions.
  • The notes carry a 0.75% annual interest rate and mature in 2030, with conversion features that allow holders to convert to Tempus Class A common stock at approximately $84.19 per share.
  • Tempus operates one of the world's largest multimodal healthcare data libraries and provides AI-powered precision medicine solutions to physicians for personalized patient care and therapeutic development.

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.